Novartis News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

24.08.21	Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma (GlobeNewswire)
03.08.21	Novartis announces lift of partial clinical trial hold and plans to initiate a new, pivotal Phase 3 study of intrathecal OAV-101 in older patients with SMA (GlobeNewswire)
21.07.21	Novartis delivered strong Q2 performance, driven by momentum of key growth brands. FY 2021 guidance unchanged. (GlobeNewswire)
21.07.21	Novartis hat im zweiten Quartal dank der Dynamik wichtiger Wachstums-marken eine starke Performance erzielt; Prognose für 2021 unverändert (GlobeNewswire)
20.07.21	Novartis pledges 10-year commitment with Morehouse School of Medicine, 26 Historically Black Colleges, Universities, Medical Schools and other leading organizations to co-create effective, measurable (GlobeNewswire)
28.06.21	Novartis appoints Rob Kowalski as Chief People & Organization Officer (GlobeNewswire)
18.06.21	New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline (GlobeNewswire)
11.06.21	Novartis investigational oral therapy iptacopan (LNP023) shows benefit as monotherapy in treatment-naïve patients with rare and life-threatening blood disorder paroxysmal nocturnal hemoglobinuria (GlobeNewswire)
06.06.21	Novartis announces iptacopan met Phase II study primary endpoint in rare kidney disease IgA nephropathy (IgAN) (GlobeNewswire)
04.06.21	Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC (GlobeNewswire)
04.06.21	Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy (GlobeNewswire)
03.06.21	Novartis reports clinically relevant improvement in median overall survival data in final analysis of pivotal NETTER-1 study with targeted radioligand therapy Lutathera (GlobeNewswire)
03.06.21	Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study (GlobeNewswire)
02.06.21	Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma (GlobeNewswire)
02.06.21	Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients (GlobeNewswire)
02.06.21	Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021 (GlobeNewswire)
01.06.21	Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis (GlobeNewswire)
28.05.21	Novartis reports one year results of Phase III MERLIN study evaluating Beovu® every four week dosing and provides update on Beovu clinical program (GlobeNewswire)
27.05.21	Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19 (GlobeNewswire)
19.05.21	Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer (GlobeNewswire)
18.05.21	Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe (GlobeNewswire)
17.05.21	US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case (GlobeNewswire)
03.05.21	Sandoz confirms late-stage clinical development plans for proposed biosimilar aflibercept, a key ophthalmology medicine (GlobeNewswire)
01.05.21	Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept (GlobeNewswire)
27.04.21	Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. (GlobeNewswire)
27.04.21	Wichtige Wachstumstreiber und Neueinführungen von Novartis setzen ihre Dynamik im ersten Quartal fort und erhalten das Vertrauen in das Wachstum; Konzernprognose für 2021 bestätigt (GlobeNewswire)
30.03.21	Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP) (GlobeNewswire)
23.03.21	Novartis announces positive result of phase III study with radioligand therapy 177Lu-PSMA-617 in patients with advanced prostate cancer (GlobeNewswire)
22.03.21	Novartis appoints Karen Hale as Chief Legal Officer (GlobeNewswire)
15.03.21	New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment (GlobeNewswire)
09.03.21	Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer (GlobeNewswire)
05.03.21	Novartis announces change to the Executive Committee (GlobeNewswire)
02.03.21	Die Aktionäre von Novartis heissen an der Generalversammlung alle Anträge des Verwaltungsrats gut (GlobeNewswire)
02.03.21	Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting (GlobeNewswire)
17.02.21	Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease (GlobeNewswire)
16.02.21	Novartis Entresto® granted expanded indication in chronic heart failure by FDA (GlobeNewswire)
11.02.21	Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics (GlobeNewswire)
29.01.21	Novartis receives positive CHMP opinion for Kesimpta®* (ofatumumab), a self-administered treatment for adult patients with relapsing multiple sclerosis (GlobeNewswire)
26.01.21	Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. (GlobeNewswire)
26.01.21	Novartis hat 2020 Umsatz und Margen gesteigert und die nächste Welle von Medikamenten weiter vorangetrieben (GlobeNewswire)
11.01.21	Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene (GlobeNewswire)
18.12.20	Novartis receives complete response letter from U.S. FDA for inclisiran (GlobeNewswire)
16.12.20	Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF (GlobeNewswire)
15.12.20	Novartis reports positive topline results from second Phase III trial of Beovu® in patients with diabetic macular edema (GlobeNewswire)
14.12.20	Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 (GlobeNewswire)
09.12.20	Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer (GlobeNewswire)
09.12.20	Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer (GlobeNewswire)
08.12.20	Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial (GlobeNewswire)
05.12.20	Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas (GlobeNewswire)
04.12.20	Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD (GlobeNewswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	545.40	2.71 %	K V
Logitech Intl	69.82	1.93 %	K V
Givaudan	3’917.00	1.40 %	K V
Swiss Re	126.85	0.71 %	K V
Roche Hldg G	250.50	0.52 %	K V
Sika	228.40	-0.61 %	K V
Kuehne+Nagel Int	206.60	-0.77 %	K V
Nestle	75.88	-0.84 %	K V
Holcim	89.32	-0.84 %	K V
CieFinRichemont	116.55	-1.73 %	K V

mehr

13:34		Bayer-Aktie in Rot: FDA erweitert Zulassung für Bayer-Krebsmedikament Nubeqa
12:26		Donnerstagshandel in Zürich: SPI zeigt sich mittags schwächer
12:26		Zuversicht in Zürich: SMI legt zu
12:26		Freundlicher Handel: DAX notiert am Donnerstagmittag im Plus
12:26		Gewinne in Zürich: So performt der SLI am Mittag
12:26		LUS-DAX-Handel aktuell: LUS-DAX liegt mittags im Minus
12:26		Anleger in Frankfurt halten sich zurück: SDAX verliert am Mittag
12:26		Schwacher Handel: Euro STOXX 50 am Donnerstagmittag in der Verlustzone